Plaque Psoriasis

After 28 weeks of treatment, tildrakizumab significantly improved clinical status and reduced disease activity while also maintaining a consistent safety profile among patients with moderate to severe plaque psoriasis, according to a study.

Risankizumab demonstrated a consistent long-term safety profile and clinical response in patients with moderate to severe plaque psoriasis, according to a phase 3 study.

Pediatric patients with palmoplantar plaque psoriasis were more likely to use combination treatment due to the inefficacy of biologics as a primary treatment in this indication, according to a study.

Recently published in the British Journal of Dermatology, AbbVie’s phase 4 head-to-head study shows risankizumab demonstrates superiority over apremilast for the treatment of adults with moderate plaque psoriasis.

In this edition, lack of sunless tanner education may cause confusion; intralesional HPV vaccine may clear recalcitrant warts; Ilumetri improves well-being of patients with plaque psoriasis and more.

Patients with Fitzpatrick skin types IV to VI with plaque psoriasis that were treated with calcipotriene/betamethasone dipropionate 0.005%/0.065% cream achieved similar rates of success as the rest of the population, according to a study.

In this edition, novel serum improves hair growth in androgenetic alopecia; cardiovascular disease linked to dermatological inflammatory diseases; sugary drinks may be associated with male pattern hair loss and more.

Ilumetri significantly improved well-being in patients with moderate to severe plaque psoriasis after 16 weeks, Almirall announced in a press release.

An oral interleukin-23 receptor antagonist peptide for adults with moderate to severe plaque psoriasis, JNJ-2113, met all endpoints in an efficacy trial and is now advancing to phase 3, according to a press release.

As age and body weight increased among secukinumab-treated pediatric patients with chronic plaque psoriasis, so did the incidence rate of adverse events, according to pooled safety data from two phase 3 studies.